Summary of "NR vs NMN vs NAM : Who Wins in Human NAD Trial?"

Concise summary

A randomized, placebo-controlled human trial (Nature Metabolism) compared three NAD precursors—nicotinamide riboside (NR), nicotinamide mononucleotide (NMN), and nicotinamide (NAM)—for their acute and 14-day effects on whole-blood NAD. NR and NMN roughly doubled baseline whole-blood NAD after 14 days; NAM produced large short-term blood spikes but did not raise baseline NAD. Gut microbiome processing (conversion of NR/NMN into nicotinic acid and use of the Preiss–Handler pathway) appears to explain the slower, sustained NAD increase with NR/NMN.

Study design and methods (key points)

Trial type: randomized, placebo-controlled human study
- 65 healthy adults, mean age 34.7
- Four arms: NR 1 g/day, NMN 1 g/day, NAM 0.5 g/day, placebo
Timeframes assessed:
- Acute pharmacokinetics: hours after a single dose
- Chronic baseline effects: after 14 days of daily dosing
Primary measurement: whole-blood NAD (reflects mainly intracellular NAD in red/white blood cells)
Supplementary experiments:
- Ex vivo/XVIVO fermentation of human gut microbiota exposed to NR, NMN, NAM
- Microbiome composition profiling and measurement of short-chain fatty acids (SCFAs)

Main findings

Chronic (14-day) effects

NR and NMN approximately doubled circulating whole-blood NAD versus placebo. The effect was similar across age and sex in this cohort.
NAM (500 mg/day) did not significantly raise baseline whole-blood NAD at the tested dose.

Acute effects

NAM caused a rapid, large spike in circulating NAD-related metabolites, peaking at roughly 1 hour post-dose.
NR and NMN were barely detectable acutely in blood despite 1 g dosing.

Gut microbiome role

Ex vivo fermentation showed gut bacteria rapidly convert NR and NMN into nicotinic acid (NA).
Converted NA is absorbed and routed into NAD synthesis via the Preiss–Handler pathway; metabolite signatures were consistent with this route.
NR supplementation was associated with increases in certain potentially beneficial gut bacterial taxa and higher SCFA production, suggesting microbial engagement, though clinical significance is unproven.

Mechanistic interpretation

Two distinct delivery routes to systemic NAD appear to operate:

NAM: rapid absorption in the upper gut → quick blood spikes via the salvage pathway; much is diverted to methylation and excretion, which may explain lack of sustained baseline increase in this study.
NR/NMN: substantial microbial processing in the gut → conversion to nicotinic acid → slower, sustained NAD synthesis via the Preiss–Handler pathway, producing higher baseline NAD over time.

Note: whole-blood NAD changes reflect systemic handling/availability but do not directly measure tissue (muscle, liver, brain) NAD.

Limitations

Short duration (14 days) — does not address long-term effects or clinical outcomes.
Young, healthy cohort (mean age ~34.7) — results may differ in older or clinical populations.
NAD measured in whole blood, not in tissues.
Microbiome changes reported are preliminary; prior longer NR trials have sometimes found no major microbiome shifts.

Takeaway

NR and NMN can raise baseline whole-blood NAD over two weeks, likely via microbiome-mediated conversion to nicotinic acid and the Preiss–Handler pathway. NAM produces large short-term blood spikes but did not increase baseline whole-blood NAD in this short study. NR/NMN and NAM differ in kinetics and likely mechanisms and are not interchangeable.

NR/NMN: slower, microbiome‑dependent route to sustained baseline NAD. NAM: fast blood spikes, but not sustained baseline increase (at tested dose/duration).

Researchers / sources featured

Randomized placebo-controlled human study published in Nature Metabolism (the trial described)
Dr. Joseph Bower (mentioned as a guest/interview source)
Dr. Lindseay Woo (mentioned as a guest/interview source)